Orphan designation was granted by the FDA to Curis (CRIS) Inc’s emavusertib for the treatment of primary central nervous system lymphoma, according to a post to the agency’s website.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter